Search clinical trials for: cMET, INC280, rosuvastatin, digoxin

Total 255 results

Novartis Pharmaceuticals

Completed

A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

cMET Dysegulation Advanced Solid Tumors

Austria, Denmark, Sweden, United Kingdom, Spain, Germany, Netherlands, United States
Novartis Pharmaceuticals

Completed

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Solid Tumors

Germany, United States, Netherlands, Spain, Canada, Hong Kong, Italy, Singapore, Australia, Israel, Korea, Republic of, Taiwan, France, Norway, Thailand
Novartis Pharmaceuticals

Terminated

Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma With c-MET Dysregulation

China, Hong Kong, Thailand, Singapore
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Spain, Switzerland, Germany, United States, Netherlands
Novartis Pharmaceuticals

Withdrawn

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma | Non-Small-Cell Lung Cancer
Novartis Pharmaceuticals

Completed

A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Novartis Pharmaceuticals

Available

Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals

Active, not recruiting

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N)

Non-small Cell Lung Cancer

United States
Massachusetts General Hospital
Novartis

Completed

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Malignant Non-small Cell Neoplasm of Lung Stage IV

United States
Novartis Pharmaceuticals

Completed

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

cMET-dysregulated Advanced Solid Tumors

United States, Italy, Spain, United Kingdom, Greece, Belgium, Austria, Czechia
Novartis Pharmaceuticals

Completed

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

cMET-dysregulated Advanced Solid Tumors

United States, Spain, Italy, Bulgaria, United Kingdom, France, Denmark
Novartis Pharmaceuticals

Active, not recruiting

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-C)

Non-Small Cell Lung Cancer (NSCLC)

China
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Germany, Australia, Hong Kong, Switzerland, Spain, France, United States
SCRI Development Innovations, LLC
Novartis

Completed

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Renal Cell Carcinoma | Colorectal Cancer | Glioblastoma Multiforme | Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Kidney Cancer

United States
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation
Pfizer

Completed

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma (LOGIC-2)

Melanoma

United States, Australia, Canada, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Metastatic Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck (SCCHN)

France, Belgium, Spain, Germany, Italy, Canada, United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Non Small Cell Lung Cancer

Canada, Spain, Australia, Singapore, Germany, Italy, Korea, Republic of, Norway, Taiwan, United States, France
Assistance Publique - Hôpitaux de Paris

Suspended

Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma (METIMGAST)

Gastric Adenocarcinoma | Oesophageal Adenocarcinoma

France
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Non-small Cell Lung Cancer

China, Taiwan, Belgium, Netherlands, Spain, Germany, Singapore, Italy, Japan, Australia, Israel, Korea, Republic of, Thailand, France
University of California, Davis
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Triple Negative Breast Cancer (TNBC)

Netherlands, Spain, Hong Kong, Singapore, Italy, Australia, Israel, Japan, United States
Novartis Pharmaceuticals

Terminated

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Non-Small Cell Lung Cancer

Italy, Singapore, Spain, Germany, Korea, Republic of, United States, Belgium, France, Netherlands, Japan
Collin Blakely
Novartis

Recruiting

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer

United States
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Advanced Hepatocellular Carcinoma

Taiwan, Canada, Italy, Korea, Republic of, Hong Kong, Germany, China, France
Novartis Pharmaceuticals

Completed

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma

China
Array BioPharma

Terminated

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)

Melanoma

Canada, Spain, Australia, Switzerland, Germany, United States
United Biomedical
Taipei Veterans General Hospital, Taiwan; Kaohsiung Veterans General Hospital. and other collaborators

Completed

Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults

HIV-1 Infection in Adults

Taiwan
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Spain, Singapore, Germany, Switzerland, Australia, France, Italy, United States
Novartis Pharmaceuticals

Completed

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Germany, France, Spain, Israel
Novartis Pharmaceuticals

Completed

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, Italy, France, Netherlands, Spain, Korea, Republic of, India, Brazil, Portugal
Actelion

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects

Safety and Tolerability

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR-mutant Non-small Cell Lung Cancer

Taiwan, Germany, Canada, Italy, Singapore, Hong Kong
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)

Melanoma

United States, Italy, United Kingdom, Netherlands, Canada, Germany, Australia, Spain, Switzerland, France
Novartis Pharmaceuticals

Terminated

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, United States, Canada, France, Italy, Japan, Korea, Republic of, Spain
Novartis Pharmaceuticals

Recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Advanced Solid Tumors Which Are cMET-dependent

Germany, Korea, Republic of, Belgium, Italy, Singapore, United States, Denmark, Spain, France, Canada
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
University of California, San Francisco

Terminated

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

ALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditions

United States
Novartis Pharmaceuticals

Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma

Korea, Republic of
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Recruiting

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)

Pediatric Cancer

Italy, France, Denmark, Germany, Netherlands, Spain, United Kingdom
Incyte Corporation

Recruiting

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics When Administered Orally to Healthy Adult Participants

Healthy Participants

United States
Jemincare

Not yet recruiting

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

Solid Tumor, Adult
Hangzhou Sciwind Biosciences Co., Ltd.

Recruiting

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Healthy Volunteers

China
Nantes University Hospital

Recruiting

Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation (EDearly AF)

Atrial Fibrillation

France
Eccogene

Recruiting

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

Type 2 Diabetes Mellitus

United States
University of Leeds

Not yet recruiting

Digoxin and Senolysis in Heart Failure and Diabetes Mellitus

Diabetes Mellitus, Type 2 | Heart Failure, Systolic

United Kingdom

Search clinical trials for: cMET, INC280, rosuvastatin, digoxin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations